New drug shows promise for Tough-to-Treat stomach cancer

NCT ID NCT07143604

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, and researchers will monitor their response and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER

Contacts and locations

Locations

Research Site

Chelyabinsk, 454092, Russia
Research Site

Krasnoyarsk, 660133, Russia
Research Site

Kuzmolovskiy, 188663, Russia
Research Site

Moscow, 111123, Russia
Research Site

Moscow, 115478, Russia
Research Site

Moscow, 115533, Russia
Research Site

Moscow, 125284, Russia
Research Site

Moscow, 142770, Russia
Research Site

Moscow, 143423, Russia
Research Site

Nizhny Novgorod, 603126, Russia
Research Site

Saint Petersburg, 197022, Russia
Research Site

Saint Petersburg, 197758, Russia
Research Site

Volgograd, Unk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.